Impact of bronchoalveolar lavage galactomannan on the outcome of patients at risk for invasive pulmonary aspergillosis

Journal of the Medical Association of Thailand

Volumn 93, Issue SUPPL 1, 2010, Pages

  Danpornprasert, Praniti ^a   Foongladda, Suporn ^a   Tscheikuna, Jamsak ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Bronchoalveolar lavage; Galactomannan antigen; Invasive pulmonary aspergillosis

Indexed keywords

ANTIFUNGAL AGENT; GALACTOMANNAN; MANNAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BRONCHOSCOPY; CHEMISTRY; FEMALE; FOLLOW UP; HUMAN; IMMUNOCOMPROMISED PATIENT; LUNG ASPERGILLOSIS; LUNG LAVAGE; LUNG MYCOSIS; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RISK; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; LUNG DISEASES, FUNGAL; MALE; MANNANS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951917885     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-15
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive asper-gillosis. N Eng J Med 2002; 347:408-15
3. Kiertiburanakul S, Thibbadee C, Santanirand P. Invasive aspergillosis in a tertiary-care hospital in Thailand. J Med Assoc Thai 2007; 90:895-902
4. Levine SJ. An approach to the diagnosis of pulmonary infections in immuno-suppressed patients. Semin Respir Infect 1992;7: 81-95
5. Pfeiffer CD., Fine JP., Safdar N. Diagnosis of Invasive Aspergillosis Using a Galactomannan Assay: A Meta-Analysis. Clin Infect Dis 2006; 42:1417-27
6. Husain S., Clancy CJ., Nguyen MH., et al. Performance characteristics of the Platelia Aspergillus EIA for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008; published online ahead of print
7. De Pauw B., Walsh TJ., Donnelly P., et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21
8. Segal BH., Herbrecht R., Stevens DA., et al. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis 2008; 47:674-83
9. Meersseman W., Lagrou K., Maertens J., et al. Galactomannan in Bronchoalveolar Lavage Fluid: A Tool for Diagnosing Aspergillosis in Intensive Care Unit Patients. Am J Respir Crit Care Med 2008;177: 27-34
10. Subira M., Martino R., Rovira M., et al. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003; 82: 80-82
11. Subira M., Martino R., Franquet T., et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haemato-logica 2002; 87:528-34
12. Suankratay C, Kanitcharaskul P, Arunyingmongkol K. Galactomannan Antigenemia for the Diagnosis of Invasive Aspergillosis in Neutropenic Patients with Hematological Disorders. J Med Assoc Thai 2006;89:1851-8